RE001 T cell

RE001 T cell is a T cell receptor engineered T cell therapy (TCR-T) designed to target KRAS G12V mutated solid tumors. This therapy involves genetically modifying a patient's own T cells by adding a specific T cell receptor that recognizes the KRAS G12V mutation, enabling the modified cells to identify and attack cancer cells harboring this mutation. Preclinical studies have demonstrated the specificity, safety, and anti-tumor activity of RE001 against KRAS mutant solid tumors[1][2]. The therapy process involves collecting peripheral blood mononuclear cells (PBMCs) from patients, genetically modifying these cells to express the specific TCR targeting KRAS G12V, expanding them in vitro, and then infusing them back into the patient. This approach is being investigated as a potential treatment option for patients with advanced solid tumors that have the KRAS G12V mutation and have not responded to conventional therapies[1].

Other names

RE001 TCR-TRE-001 TCR-TRE 001 TCR-T